Sabby Management’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-2,014,787
Closed -$62.4M 309
2016
Q4
$55.3M Buy
2,014,787
+1,478,505
+276% +$59.4M 3.22% 7
2016
Q3
$32.9M Sell
536,282
-247,215
-32% -$7.47M 1.23% 14
2016
Q2
$14.9M Buy
783,497
+277,560
+55% +$5.14M 0.78% 25
2016
Q1
$9.88M Buy
+505,937
New +$8.84M 0.49% 24
2015
Q3
Sell
-71,600
Closed -$2.43M 399
2015
Q2
$2.18M Buy
71,600
+49,657
+226% +$1.02M 0.08% 158
2015
Q1
$291K Sell
21,943
-83,057
-79% -$1.11M 0.01% 255
2014
Q4
$1.52K Sell
105,000
-1,663
-2% -$28.2K 0.05% 143
2014
Q3
$2.25K Sell
106,663
-20,109
-16% -$454K 0.09% 100
2014
Q2
$3.78M Sell
126,772
-225,328
-64% -$7.12M 0.16% 72
2014
Q1
$8.46M Sell
352,100
-155,600
-31% -$3.97M 0.47% 49
2013
Q4
$10.3M Sell
507,700
-14,341
-3% -$426K 0.66% 34
2013
Q3
$24.7M Buy
522,041
+67,142
+15% +$2.59M 1.6% 17
2013
Q2
$17.3M Buy
+454,899
New +$16.3M 1.16% 21

Other funds holding SRPT

Sabby Management's SRPT Position: Q1 2017 in Review

Sabby Management sold out of Sarepta Therapeutics (SRPT) in Q1 2017, closing a stake of 2,014,787 shares — an estimated $62.4M sold.

Sabby Management first reported a position in SRPT in Q2 2013 and held it in 13 quarters. The position peaked at $55.3M in Q4 2016. 179 funds tracked by Wall St. Rank hold SRPT as of Q1 2017.

  • Sabby Management reported no remaining Sarepta Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 2,014,787 Sarepta Therapeutics shares in Q1 2017, an estimated $62.4M.
  • Sabby Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 13 quarters.
  • Sabby Management's Sarepta Therapeutics position peaked at $55.3M in Q4 2016.
  • 179 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.